1192885-87-2

Upstream product

• 1217181-38-8 2-(2-chloropyridin-4-yl)-1-(3-methoxy-5-methylphenyl)ethanone 
• 108593-44-8 methyl 3-methoxy-5-methylbenzoate 
• 3678-62-4 2-chloro-4-picoline 
• 585-81-9 3-hydroxy-5-methylbenzoic acid 
• 624-75-9 iodoacetonitrile 
• 1192885-45-2 2-chloro-4-(3-(3-methoxy-5-methylphenyl)-1H-pyrazol-4-yl)pyridine 
• 51067-38-0 4-phenoxyphenylboronic acid 

Downstream Products

• 1192886-15-9 2-(5-(3-hydroxy-5-methylphenyl)-4-(2-(4-phenoxyphenyl)pyridin-4-yl)-1H-pyrazol-1-yl)acetonitrile 

Relevant academic research and scientific papers

PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE

Disclosed herein are novel pyrazole compounds, pharmaceutically acceptable salts thereof, a method for preparing the same, and uses thereof as anticancer agents.

Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity

A new series of 1H- and 2H-pyrazole derivatives (35 final compounds) has been designed and synthesized in this study. A selected group (13 compounds) was then tested over a panel of 60 cancer cell lines at a single dose concentration of 10 μM. At this concentration, six compounds have showed moderate to strong mean inhibitions, and were further tested at five-dose testing mode to determine their IC50 over the 60 cell lines. The IC50 values of the tested compounds indicated high potency (as for compound 10f) as well as high efficacy (as for compound 11e). Accordingly, compound 10f was then tested at a single dose concentration of 10 μM over a panel of 54 kinases to determine its kinase inhibitory profile. The compound has showed good selectivity towards FLT3 kinase, associated with a moderate potency, with an IC50 value of 1.74 μM.

Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors

A series of rationally designed ROS1 tyrosine kinase inhibitors was synthesized and screened. Compound 12b has showed good potency with IC50 value of 209 nM, which is comparable with that of the reference lead compound 1. Molecular modeling studies have been performed, that is, a homology model for ROS1 was built, and the screened inhibitors were docked into its major identified binding site. The docked poses along with the activity data have revealed a group of the essential features for activity. Overall, simplification of the lead compound 1 into compound 12b has maintained the activity, while facilitated the synthetic advantages. A molecular interaction model for ROS1 kinase and inhibitors has been proposed.